newsfilter
← Latest News
GlobeNewswire·

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

APR-1051 (WEE1 kinase inhibitor): In ongoing Phase 1 ACESOT-1051dose-escalation trial, 3 out of 4 patients at Dose Level 6 (100 mg once daily) achieved stable disease, per RECIST v1.1, in heavily pretreated